Exact Mass: 725.559409
Exact Mass Matches: 725.559409
Found 500 metabolites which its exact mass value is equals to given mass value 725.559409,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
GlcCer(d18:1/9Z-18:1)
GlcCer(d18:1/9Z-18:1) is a glycosphingolipid (ceramide and oligosaccharide)or oligoglycosylceramide with one or more sialic acids (i.e. n-acetylneuraminic acid) linked on the sugar chain. It is a component the cell plasma membrane which modulates cell signal transduction events. Gangliosides have been found to be highly important in immunology. Ganglioside GL1a carries a net-negative charge at pH 7.0 and is acidic. Gangliosides can amount to 6\\% of the weight of lipids from brain, but they are found at low levels in all animal tissues.Cerebrosides are glycosphingolipids. There are four types of glycosphingolipids, the cerebrosides, sulfatides, globosides and gangliosides. Cerebrosides have a single sugar group linked to ceramide. The most common are galactocerebrosides (containing galactose), the least common are glucocerebrosides (containing glucose). Galactocerebrosides are found predominantly in neuronal cell membranes. In contrast glucocerebrosides are not normally found in membranes. Instead, they are typically intermediates in the synthesis or degradation of more complex glycosphingolipids. Galactocerebrosides are synthesized from ceramide and UDP-galactose. Excess lysosomal accumulation of glucocerebrosides is found in Gaucher disease. A glycosphingolipid (ceramide and oligosaccharide)or oligoglycosylceramide with one or more sialic acids (i.e. n-acetylneuraminic acid) linked on the sugar chain. It is a component the cell plasma membrane which modulates cell signal transduction events. Gangliosides have been found to be highly important in immunology. Ganglioside GL1a carries a net-negative charge at pH 7.0 and is acidic. Gangliosides can amount to 6\\% of the weight of lipids from brain, but they are found at low levels in all animal tissues.
PE(18:2(9Z,12Z)/P-18:1(11Z))
PE(18:2(9Z,12Z)/P-18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:2(9Z,12Z)/P-18:1(11Z)), in particular, consists of one chain of linoleic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The linoleic acid moiety is derived from seed oils, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(18:2(9Z,12Z)/P-18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:2(9Z,12Z)/P-18:1(11Z)), in particular, consists of one chain of linoleic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The linoleic acid moiety is derived from seed oils, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(18:2(9Z,12Z)/P-18:1(9Z))
PE(18:2(9Z,12Z)/P-18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:2(9Z,12Z)/P-18:1(9Z)), in particular, consists of one chain of linoleic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The linoleic acid moiety is derived from seed oils, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PE(18:3(6Z,9Z,12Z)/P-18:0)
PE(18:3(6Z,9Z,12Z)/P-18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:3(6Z,9Z,12Z)/P-18:0), in particular, consists of one chain of g-linolenic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The g-linolenic acid moiety is derived from animal fats, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(18:3(6Z,9Z,12Z)/P-18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:3(6Z,9Z,12Z)/P-18:0), in particular, consists of one chain of g-linolenic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The g-linolenic acid moiety is derived from animal fats, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(18:3(9Z,12Z,15Z)/P-18:0)
PE(18:3(9Z,12Z,15Z)/P-18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:3(9Z,12Z,15Z)/P-18:0), in particular, consists of one chain of a-linolenic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The a-linolenic acid moiety is derived from seed oils, especially canola and soybean oil, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PE(20:3(5Z,8Z,11Z)/P-16:0)
PE(20:3(5Z,8Z,11Z)/P-16:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:3(5Z,8Z,11Z)/P-16:0), in particular, consists of one chain of mead acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The mead acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(20:3(5Z,8Z,11Z)/P-16:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:3(5Z,8Z,11Z)/P-16:0), in particular, consists of one chain of mead acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The mead acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(20:3(8Z,11Z,14Z)/P-16:0)
PE(20:3(8Z,11Z,14Z)/P-16:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:3(8Z,11Z,14Z)/P-16:0), in particular, consists of one chain of homo-g-linolenic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The homo-g-linolenic acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(20:3(8Z,11Z,14Z)/P-16:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:3(8Z,11Z,14Z)/P-16:0), in particular, consists of one chain of homo-g-linolenic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The homo-g-linolenic acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
Galactosylceramide (d18:1/18:1(9Z))
Galactosylceramides (GalCer) are non-acidic monoglycosphingolipids, i.e. a sphingolipid with one carbohydrate moiety attached to a ceramide unit. They are an intermediate in sphingolipid metabolism and is the second to last step in the synthesis of digalactosylceramidesulfate. GalCer is generated from ceramide via the enzyme UDP-galactose ceramide galactosyltransferase [EC:2.4.1.47]. It can be converted to digalactosylceramide via the enzyme glycosyltransferases [EC 2.4.1.-]. Galactosylceramide is the principal glycosphingolipid in brain tissue, hence the trivial name "cerebroside", which was first conferred on it in 1874. Galactosylceramides are found in all nervous tissues, but they can amount to 2\\% of the dry weight of grey matter and 12\\% of white matter. They are major constituents of oligodendrocytes. Synthesis of galactosylceramide takes place on the lumenal surface of the endoplasmic reticulum, although it has free access to the cytosolic surface by an energy-independent flip-flop process. GalCer sits in the extracellular leaflet of cell membranes in nanometer sized domains or rafts. The local clustering of GalCer within rafts is thought to facilitate the initial adhesion of certain viruses, including HIV-1 and bacteria to cells through multivalent interactions between receptor proteins and GalCer. A defect in the degradation of cerbrosides leads to a disorder called Krabbe disease. Krabbe disease (also known as globoid cell leukodystrophy or galactosylceramide lipidosis) is a rare, often fatal degenerative disorder that affects the myelin sheath of the nervous system. Krabbe disease is caused by mutations in the GALC gene, which causes a deficiency of galactosylceramidase. Infants with Krabbe disease are normal at birth. Symptoms begin between the ages of 3 and 6 months with irritability, fevers, limb stiffness, seizures, feeding difficulties, vomiting, and slowing of mental and motor development. There are also juvenile- and adult-onset cases of Krabbe disease, which have similar symptoms but slower progression. In infants, the disease is generally fatal before age 2. Patients with late-onset Krabbe disease tend to have a slower progression of the disease and live significantly longer.Cerebrosides are glycosphingolipids. There are four types of glycosphingolipids, the cerebrosides, sulfatides, globosides and gangliosides. Cerebrosides have a single sugar group linked to ceramide. The most common are galactocerebrosides (containing galactose), the least common are glucocerebrosides (containing glucose). Galactocerebrosides are found predominantly in neuronal cell membranes. In contrast glucocerebrosides are not normally found in membranes. Instead, they are typically intermediates in the synthesis or degradation of more complex glycosphingolipids. Galactocerebrosides are synthesized from ceramide and UDP-galactose. Excess lysosomal accumulation of glucocerebrosides is found in Gaucher disease. Galactosylceramide (GalCer) is a non-acidic monoglycosphingolipid, i.e. a sphingolipid with one carbohydrate moiety attached to a ceramide unit. It is an intermediate in sphingolipid metabolism and is the second to last step in the synthesis of digalactosylceramidesulfate. GalCer is generated from ceramide via the enzyme UDP-galactose ceramide galactosyltransferase [EC:2.4.1.47]. It can be converted to digalactosylceramide via the enzyme glycosyltransferases [EC 2.4.1.-]. Galactosylceramide is the principal glycosphingolipid in brain tissue, hence the trivial name "cerebroside", which was first conferred on it in 1874. Galactosylceramides are found in all nervous tissues, but they can amount to 2\\% of the dry weight of grey matter and 12\\% of white matter. They are major constituents of oligodendrocytes. Synthesis of galactosylceramide takes place on the lumenal surface of the endoplasmic reticulum, although it has free access to the cytosolic surface by an energy-independent flip-flop process. GalCer sits in the extracellular leaflet of cell membranes in nanometer sized domains or rafts. The local clustering of GalCer within rafts is thought to facilitate the initial adhesion of certain viruses, including HIV-1 and bacteria to cells through multivalent interactions between receptor proteins and GalCer. A defect in the degradation of cerbrosides leads to a disorder called Krabbe disease. Krabbe disease (also known as globoid cell leukodystrophy or galactosylceramide lipidosis) is a rare, often fatal degenerative disorder that affects the myelin sheath of the nervous system. Krabbe disease is caused by mutations in the GALC gene, which causes a deficiency of galactosylceramidase. Infants with Krabbe disease are normal at birth. Symptoms begin between the ages of 3 and 6 months with irritability, fevers, limb stiffness, seizures, feeding difficulties, vomiting, and slowing of mental and motor development. There are also juvenile- and adult-onset cases of Krabbe disease, which have similar symptoms but slower progression. In infants, the disease is generally fatal before age 2. Patients with late-onset Krabbe disease tend to have a slower progression of the disease and live significantly longer.
PE(P-16:0/20:3(5Z,8Z,11Z))
PE(P-16:0/20:3(5Z,8Z,11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-16:0/20:3(5Z,8Z,11Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of mead acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the mead acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PE(P-16:0/20:3(8Z,11Z,14Z))
PE(P-16:0/20:3(8Z,11Z,14Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-16:0/20:3(8Z,11Z,14Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of homo-g-linolenic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the homo-g-linolenic acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-16:0/20:3(8Z,11Z,14Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-16:0/20:3(8Z,11Z,14Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of homo-g-linolenic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the homo-g-linolenic acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(P-18:0/18:3(6Z,9Z,12Z))
PE(P-18:0/18:3(6Z,9Z,12Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:0/18:3(6Z,9Z,12Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of g-linolenic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the g-linolenic acid moiety is derived from animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:0/18:3(6Z,9Z,12Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:0/18:3(6Z,9Z,12Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of g-linolenic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the g-linolenic acid moiety is derived from animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(P-18:0/18:3(9Z,12Z,15Z))
PE(P-18:0/18:3(9Z,12Z,15Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:0/18:3(9Z,12Z,15Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of a-linolenic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the a-linolenic acid moiety is derived from seed oils, especially canola and soybean oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:0/18:3(9Z,12Z,15Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:0/18:3(9Z,12Z,15Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of a-linolenic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the a-linolenic acid moiety is derived from seed oils, especially canola and soybean oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(P-18:1(11Z)/18:2(9Z,12Z))
PE(P-18:1(11Z)/18:2(9Z,12Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(11Z)/18:2(9Z,12Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of linoleic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the linoleic acid moiety is derived from seed oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:1(11Z)/18:2(9Z,12Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(11Z)/18:2(9Z,12Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of linoleic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the linoleic acid moiety is derived from seed oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(P-18:1(9Z)/18:2(9Z,12Z))
PE(P-18:1(9Z)/18:2(9Z,12Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(9Z)/18:2(9Z,12Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of linoleic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the linoleic acid moiety is derived from seed oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
1-O-(beta-D-glucopyranosyl)-(2S,3R,4E,8E)-2-(octadecanoylamino)-4,8-octadecadiene-1,3-diol
1-O-(beta-D-glucopyranosyl)-(2S,3R,4E,8E,10E)-2-[(2R)-2-(hydroxyhexadecanoyl)amido]-9-methyl-4,8,10-octadecatriene-1,3-diol|phalluside 1
1-(((2-aminoethoxy)(hydroxy)phosphoryl)oxy)-3-(hexadecyloxy)propan-2-yl-icosa-5.8.11.14-tetraenoate
1-tetradecanyl-2-(8-[3]-ladderane-octanyl)-sn-glycerophosphocholine
C42H80NO6P (725.5722949999999)
PE(O-18:0/18:4(6Z,9Z,12Z,15Z))
PC dO-34:4
C42H80NO6P (725.5722949999999)
Chrysogeside B
A glucosylceramide isolated from Penicillium chrysogenum.
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C40H74N2O7P+ (725.5233364000001)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C40H74N2O7P+ (725.5233364000001)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C40H74N2O7P+ (725.5233364000001)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C40H74N2O7P+ (725.5233364000001)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexadecoxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexadec-9-enoxy]propan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propan-2-yl] (Z)-octadec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propan-2-yl] hexadecanoate
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (24Z,27Z,30Z,33Z)-hexatriaconta-24,27,30,33-tetraenoate
[3-nonoxy-2-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
(5Z,8Z,11Z,14Z,17Z,20Z,23Z,26Z,29Z)-N-[(4E,8E,12E)-1,3-dihydroxyheptadeca-4,8,12-trien-2-yl]dotriaconta-5,8,11,14,17,20,23,26,29-nonaenamide
(7Z,10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z)-N-[(4E,8E,12E)-1,3-dihydroxypentadeca-4,8,12-trien-2-yl]tetratriaconta-7,10,13,16,19,22,25,28,31-nonaenamide
(7Z,10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z,34Z,37Z)-N-[(E)-1,3-dihydroxynon-4-en-2-yl]tetraconta-7,10,13,16,19,22,25,28,31,34,37-undecaenamide
2-[3-octanoyloxy-2-[(Z)-tetracos-13-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-nonadecanoyloxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-dodecanoyloxy-2-[(Z)-icos-11-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-heptadecanoyloxy-2-[(Z)-pentadec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-decanoyloxy-2-[(Z)-docos-13-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-hexadecanoyloxy-2-[(Z)-hexadec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(Z)-henicos-11-enoyl]oxy-3-undecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(Z)-heptadec-9-enoyl]oxy-3-pentadecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(Z)-nonadec-9-enoyl]oxy-3-tridecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-octadecanoyloxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(Z)-octadec-9-enoyl]oxy-3-tetradecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
(6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z)-N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]hexatriaconta-6,9,12,15,18,21,24,27,30,33-decaenamide
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxyhexadec-7-enoyl]amino]hexacosa-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxytetracos-11-enoyl]amino]octadeca-4,8-diene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxyoctadecanoylamino)tetracosa-4,8,12-triene-1-sulfonic acid
(E)-3-hydroxy-2-[[(4Z,7Z)-2-hydroxyhexadeca-4,7-dienoyl]amino]hexacos-4-ene-1-sulfonic acid
(E)-3-hydroxy-2-[[(14Z,16Z)-2-hydroxydocosa-14,16-dienoyl]amino]icos-4-ene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxynonadecanoylamino)tricosa-4,8,12-triene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxyicos-11-enoyl]amino]docosa-4,8-diene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxydocosanoylamino)icosa-4,8,12-triene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxyhexadecanoylamino)hexacosa-4,8,12-triene-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl] (16Z,19Z,22Z,25Z)-octacosa-16,19,22,25-tetraenoate
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxypentacos-11-enoyl]amino]heptadeca-4,8-diene-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(16Z,19Z,22Z,25Z)-octacosa-16,19,22,25-tetraenoxy]propan-2-yl] octanoate
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxyhexacos-11-enoyl]amino]hexadeca-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxytricos-11-enoyl]amino]nonadeca-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxyhenicos-9-enoyl]amino]henicosa-4,8-diene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxypentacosanoylamino)heptadeca-4,8,12-triene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxyhexacosanoylamino)hexadeca-4,8,12-triene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxytricosanoylamino)nonadeca-4,8,12-triene-1-sulfonic acid
(E)-3-hydroxy-2-[[(18Z,21Z)-2-hydroxytetracosa-18,21-dienoyl]amino]octadec-4-ene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxydocos-11-enoyl]amino]icosa-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxyoctadec-11-enoyl]amino]tetracosa-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxynonadec-9-enoyl]amino]tricosa-4,8-diene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxytetracosanoylamino)octadeca-4,8,12-triene-1-sulfonic acid
(E)-3-hydroxy-2-[[(11Z,14Z)-2-hydroxyicosa-11,14-dienoyl]amino]docos-4-ene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxyheptadecanoylamino)pentacosa-4,8,12-triene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxyicosanoylamino)docosa-4,8,12-triene-1-sulfonic acid
(E)-3-hydroxy-2-[[(11Z,14Z)-2-hydroxyhexacosa-11,14-dienoyl]amino]hexadec-4-ene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxyhenicosanoylamino)henicosa-4,8,12-triene-1-sulfonic acid
(E)-3-hydroxy-2-[[(10Z,12Z)-2-hydroxyoctadeca-10,12-dienoyl]amino]tetracos-4-ene-1-sulfonic acid
[2-nonanoyloxy-3-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-heptanoyloxy-3-[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(16Z,19Z,22Z,25Z)-octacosa-16,19,22,25-tetraenoxy]-2-pentanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
(E)-3-hydroxy-2-[[(Z)-nonadec-9-enoyl]amino]tetracos-4-ene-1-sulfonic acid
C43H83NO5S (725.5991627999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate
(4E,8E)-2-(heptadecanoylamino)-3-hydroxyhexacosa-4,8-diene-1-sulfonic acid
C43H83NO5S (725.5991627999999)
(4E,8E)-3-hydroxy-2-(tetracosanoylamino)nonadeca-4,8-diene-1-sulfonic acid
C43H83NO5S (725.5991627999999)
(4E,8E)-2-(docosanoylamino)-3-hydroxyhenicosa-4,8-diene-1-sulfonic acid
C43H83NO5S (725.5991627999999)
(4E,8E)-3-hydroxy-2-(pentacosanoylamino)octadeca-4,8-diene-1-sulfonic acid
C43H83NO5S (725.5991627999999)
(E)-3-hydroxy-2-[[(Z)-tetracos-13-enoyl]amino]nonadec-4-ene-1-sulfonic acid
C43H83NO5S (725.5991627999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoxy]propan-2-yl] decanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-icos-11-enoxy]propan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] icosanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-decoxypropan-2-yl] (14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-icosoxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoxy]propan-2-yl] dodecanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propan-2-yl] (Z)-icos-11-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-heptadeca-9,12-dienoxy]propan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-icosa-11,14-dienoxy]propan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-dodecoxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate
[3-heptadecoxy-2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]oxy-3-[(Z)-tridec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(Z)-heptadec-9-enoxy]-2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-heptadecanoyloxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxy-3-[(Z)-pentadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxy-3-tridecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(Z)-heptadec-9-enoyl]oxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxy-3-pentadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(9Z,12Z)-heptadeca-9,12-dienoxy]-2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]oxy-3-undecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-[4-[12-hydroxy-10,13-dimethyl-3-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxy-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]acetic acid
2-[4-[3-[(Z)-icos-11-enoyl]oxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]acetic acid
4-[3-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octadecoxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
[3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]-2-tridecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoxy]-2-undecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-octadec-9-enoxy]propan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoxy]propan-2-yl] tetradecanoate
[3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]-2-pentadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z)-docosa-10,13,16-trienoxy]propan-2-yl] (Z)-tetradec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate
[3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]-2-[(Z)-pentadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] octadecanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propan-2-yl] (11Z,14Z)-icosa-11,14-dienoate
[3-[(11Z,14Z,17Z)-icosa-11,14,17-trienoxy]-2-[(Z)-tridec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tetradecoxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z,17Z)-icosa-11,14,17-trienoxy]propan-2-yl] (Z)-hexadec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexadecoxypropan-2-yl] (4Z,7Z,10Z,13Z)-icosa-4,7,10,13-tetraenoate
(Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]octadec-11-enamide
(10Z,12Z)-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadecan-2-yl]octadeca-10,12-dienamide
(4Z,7Z)-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosan-2-yl]hexadeca-4,7-dienamide
(Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicos-4-en-2-yl]hexadec-7-enamide
(Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadec-4-en-2-yl]henicos-9-enamide
(Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytricos-4-en-2-yl]tridec-8-enamide
(Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradec-4-en-2-yl]docos-11-enamide
(Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetracos-4-en-2-yl]dodec-5-enamide
(14Z,16Z)-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradecan-2-yl]docosa-14,16-dienamide
(E)-N-[(E,2S,3R)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicos-8-en-2-yl]hexadec-9-enamide
4-[3-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-2-[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
(E)-N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-8-en-2-yl]heptadec-9-enamide
(E)-N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]heptadec-9-enamide
4-[3-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-2-[(11E,13E,15E)-octadeca-11,13,15-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(2S,3R,4E,8E)-3-hydroxy-2-[[(9E,12E)-octadeca-9,12-dienoyl]amino]octadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
(E)-N-[(E,2S,3R)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicos-4-en-2-yl]hexadec-9-enamide
4-[3-[(5E,8E,11E,14E,17E,20E)-tricosa-5,8,11,14,17,20-hexaenoyl]oxy-2-[(E)-undec-4-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(2S,3R,4E,14E)-3-hydroxy-2-[[(9E,12E)-octadeca-9,12-dienoyl]amino]octadeca-4,14-dienoxy]phosphoryl]oxyethyl-trimethylazanium
N-[(2S,3R,4E,6E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadeca-4,6-dien-2-yl]icosanamide
N-[(2S,3R,4E,6E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradeca-4,6-dien-2-yl]docosanamide
N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhenicosa-4,8-dien-2-yl]pentadecanamide
4-[2-[(4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoyl]oxy-3-[(9E,12E)-pentadeca-9,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(7E,10E,13E,16E)-nonadeca-7,10,13,16-tetraenoyl]oxy-3-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadeca-4,8-dien-2-yl]henicosanamide
4-[3-[(10E,13E,16E,19E)-docosa-10,13,16,19-tetraenoyl]oxy-2-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradeca-4,8-dien-2-yl]docosanamide
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-octadec-1-enoxy]propan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate
4-[3-[(E)-dec-4-enoyl]oxy-2-[(6E,9E,12E,15E,18E,21E)-tetracosa-6,9,12,15,18,21-hexaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(4E,7E)-deca-4,7-dienoyl]oxy-2-[(6E,9E,12E,15E,18E)-tetracosa-6,9,12,15,18-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosa-4,8-dien-2-yl]hexadecanamide
N-[(2S,3R,4E,14E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,14-dien-2-yl]octadecanamide
4-[2-[(4E,7E)-deca-4,7-dienoyl]oxy-3-[(6E,9E,12E,15E,18E)-tetracosa-6,9,12,15,18-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-[(E)-dodec-5-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
(E)-N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadec-4-en-2-yl]icos-11-enamide
4-[2-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
(9E,12E)-N-[(2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadecan-2-yl]octadeca-9,12-dienamide
(E)-N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]octadec-9-enamide
4-[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(11E,13E,15E)-octadeca-11,13,15-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-2-[(E)-dodec-5-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-octadec-1-enoxy]propan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate
4-[2-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxy-3-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-hexadec-1-enoxy]propan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate
4-[2-[(10E,13E,16E,19E)-docosa-10,13,16,19-tetraenoyl]oxy-3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
(E)-N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradec-4-en-2-yl]docos-13-enamide
4-[3-[(7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoyl]oxy-2-[(6E,9E)-dodeca-6,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-dec-4-enoyl]oxy-3-[(6E,9E,12E,15E,18E,21E)-tetracosa-6,9,12,15,18,21-hexaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-2-[(10E,12E)-octadeca-10,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-hexadec-1-enoxy]propan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate
4-[3-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(7E,10E,13E,16E)-nonadeca-7,10,13,16-tetraenoyl]oxy-2-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxy-2-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxy-2-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
(E)-N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradec-8-en-2-yl]docos-13-enamide
4-[3-[(7E,9E,11E,13E,15E,17E)-icosa-7,9,11,13,15,17-hexaenoyl]oxy-2-[(E)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]octadecanamide
4-[2-[(7E,9E,11E,13E,15E,17E)-icosa-7,9,11,13,15,17-hexaenoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadeca-4,8-dien-2-yl]heptadecanamide
(E)-N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadec-8-en-2-yl]icos-11-enamide
N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptadeca-4,8-dien-2-yl]nonadecanamide
4-[2-[(7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoyl]oxy-3-[(6E,9E)-dodeca-6,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(5E,8E,11E,14E,17E,20E)-tricosa-5,8,11,14,17,20-hexaenoyl]oxy-3-[(E)-undec-4-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadeca-4,8-dien-2-yl]icosanamide
4-[2-[(7E,9E,11E,13E,15E,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoyl]oxy-3-dodecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoyl]oxy-2-[(9E,12E)-pentadeca-9,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(10E,12E)-octadeca-10,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
(E)-N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-8-en-2-yl]octadec-9-enamide
4-[3-[(7E,9E,11E,13E,15E,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoyl]oxy-2-dodecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxydocosa-4,8-dien-2-yl]tetradecanamide
N-[(2S,3R,4E,6E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadeca-4,6-dien-2-yl]henicosanamide
4-[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[[(4E,8E,12E)-2-[[(Z)-hexadec-7-enoyl]amino]-3-hydroxyicosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(Z)-nonadec-9-enoyl]amino]heptadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-[[(Z)-dodec-5-enoyl]amino]-3-hydroxytetracosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]docosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-[[(Z)-docos-11-enoyl]amino]-3-hydroxytetradeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(11Z,14Z)-icosa-11,14-dienoyl]amino]hexadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(10Z,12Z)-octadeca-10,12-dienoyl]amino]octadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(Z)-tridec-8-enoyl]amino]tricosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(14Z,16Z)-docosa-14,16-dienoyl]amino]-3-hydroxytetradeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]henicosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(4Z,7Z)-hexadeca-4,7-dienoyl]amino]-3-hydroxyicosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-[[(Z)-henicos-9-enoyl]amino]-3-hydroxypentadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(Z)-icos-11-enoyl]amino]hexadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(Z)-octadec-11-enoyl]amino]octadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-[[(Z)-henicos-11-enoyl]amino]-3-hydroxypentadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-[[(Z)-heptadec-9-enoyl]amino]-3-hydroxynonadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(9Z,12Z)-octadeca-9,12-dienoyl]amino]octadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(Z)-octadec-9-enoyl]amino]octadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]amino]-3-hydroxytetradec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(13Z,16Z)-docosa-13,16-dienoyl]amino]-3-hydroxytetradeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoyl]amino]-3-hydroxydecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoyl]amino]dodecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(8E,12E,16E)-2-[[(9Z,12Z)-heptadeca-9,12-dienoyl]amino]-3,4-dihydroxyoctadeca-8,12,16-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C40H74N2O7P+ (725.5233364000001)
2-[[(E)-2-[[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoyl]amino]-3-hydroxydec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]amino]hexadecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-[[(Z)-docos-13-enoyl]amino]-3-hydroxytetradeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]amino]octadecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]amino]-3-hydroxyicosoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(9Z,12Z)-nonadeca-9,12-dienoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]amino]-3-hydroxytetradecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(14Z,17Z,20Z)-octacosa-14,17,20-trienoyl]amino]oct-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]amino]-3-hydroxyicos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(9Z,12Z)-hexadeca-9,12-dienoyl]amino]-3-hydroxyicosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]tricosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]amino]hexadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(9Z,12Z)-heptadeca-9,12-dienoyl]amino]-3-hydroxynonadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoyl]amino]dodec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-[[(Z)-hexadec-9-enoyl]amino]-3-hydroxyicosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(11Z,14Z)-henicosa-11,14-dienoyl]amino]-3-hydroxypentadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(13Z,16Z)-tetracosa-13,16-dienoyl]amino]dodeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(16Z,19Z,22Z,25Z)-octacosa-16,19,22,25-tetraenoyl]amino]octoxy]phosphoryl]oxyethyl-trimethylazanium
beta-D-glucosyl-N-(oleoyl)sphingosine
An N-acyl-beta-D-galactosylsphingosine where the ceramide N-acyl group is specified as oleoyl.
1-(1Z-hexadecenyl)-2-(8Z,11Z,14Z-icosatrienoyl)-sn-glycero-3-phosphoethanolamine
A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine in which the alkyl and the acyl groups at positions 1 and 2 are specified as (1Z)-hexadecenyl and (8Z,11Z,14Z)-icosatrienoyl respectively.
1-(beta-D-galactosyl)-N-octadecenoylsphingosine
A D-galactosyl-N-acylsphingosine in which the fatty acyl group contains 18 carbons and 1 double bond.
phosphatidylethanolamine P-36:3
A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine zwitterion in which the alk-1-enyl and acyl groups at positions 1 and 2 contain 36 carbon atoms in total with 3 additional double bonds.
1-(1Z,11Z-Octadecadienyl)-2-linoleoyl-sn-glycero-3-phosphoethanolamine
A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine in which the alkyl and the acyl groups at positions 1 and 2 are specified as (1Z,11Z)-octadecadienyl and linoleoyl respectively.
MePC(32:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Hex1Cer(36:2)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Hex1Cer(35:3)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
dMePE(34:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved